Browse a selection of key resources and publications about our pipeline.

CLN-978: Mechanism of Action: T Cell Engagers

Mechanism of Action: T Cell Engagers

Modulating the Immune System: An Intricate Balancing Act

Advances in Autoimmune Diseases: A Conversation with Dr. Ricardo Grieshaber-Bouyer

CLN-978, A CD19-Directed T-Cell Engager (TCE), Leads to Rapid and Deep B-Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases (2024 ACR)

Safety and Antitumor Activity of Zipalertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutations Who Received Prior Amivantamab (2024 ESMO)

Pharmacodynamic Activities of the Anti-MICA/B Monoclonal Antibody CLN-619, Evaluated as a Monotherapy, Support the Proposed Mechanisms of Action and Correlate With Response (2024 SITC)

CLN-619 Mechanism of Action

Expression MICA/B (MHC Class I Chain-Related Protein A and B)

CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab for Advanced Solid Tumors: Updated Results of a Phase 1 Study (2024 ASCO)